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Introduction. Clinical presentation of viral hepatitis ranges from mild symptoms to fulminant hepatitis. Our aim is to describe
clinical presentation and outcomes of children with viral hepatitis from the Eastern Ontario/Western Quebec regions of Canada.
Methods.Retrospective chartreview ofchildren diagnosedwithviralhepatitisatourinstitutionfromJanuary1,1998,to December
31, 2007. Results. There were 261 charts reviewed, only 64 had a conﬁrmed viral etiology: 34 (53%) hepatitis B (HBV), 16 (25%)
hepatitis C (HCV), 4 (6.3%) hepatitis A (HAV), 7 (11%) cytomegalovirus (CMV), and 3 (4.7%) Epstein-Barr virus (EBV).
Children with HBV presented at a mean age of 6.4 ± 4.6years. Spontaneous seroconversion (appearance of HBVeAb and loss
of HBVeAg) occurred in 21/34 (61.7%). Children with acute hepatitis (HAV, CMV, and EBV) presented with mild abdominal
pain, jaundice, and fevers. Overall outcome was excellent. Conclusion. Acute and chronic hepatitis in children has a benign course;
moreover, HBV spontaneous seroconversionis commonin pediatric patients.
1.Introduction
Hepatitis in childhood is largely caused by viral etiology.
Clinical presentation of acute hepatitis generally includes
jaundice and vague abdominal pain, though some children
may present with vomiting and fever. These symptoms are
reported to be milder and the disease course is shorter
in children compared to adults [1]. Children with chronic
hepatitis rarely present with symptoms; its prevalence is
inﬂuenced by country of origin, socioeconomic status, and
local outbreaks.
The incidence of viral hepatitis varies according to
geographical areas [2] as well as immunization regime in
diﬀerentcountries.TheprevalenceofhepatitisBinCanadian
children has been estimated between 5 and 13 per 100,000
[3]. Approximately2 billionpeople haveserological evidence
of past or current hepatitis B infection in the world;
however,globalpediatricprevalenceisnotknown[4].Nearly
90% of viral hepatitis is caused by hepatitis A, B, or C
viruses [5]; however, potential hepatotropic viruses that can
cause acute hepatitis include Epstein-Barr virus (EBV) and
cytomegalovirus (CMV).
Our aim is to describe clinical presentation and outcome
of patients diagnosed with viral hepatitis in the national
capital region of Canada.
2.Methods
We conducted a retrospective chart review of all patients
diagnosed with viral hepatitis including hepatitis A, B, and
C, EBV, and CMV from January 1998 to January 2008 at the
Children’s Hospital of Eastern Ontario.
Demographics included age at diagnosis, gender, and
ethnic background [6]. Symptoms at presentation such as
jaundice, abdominal pain, vomiting, and fever as well as the
need for admission to hospital were recorded. Biochemical
parameters included alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), alkaline phosphatase, gamma2 ISRN Pediatrics
Table 1: Acute hepatitis, demographics, and clinical presentation.
Virus (N) Age at diagnosis:years ± SD Signs and symptoms ALT (IU/mL, median, interquartile range) P value∗
HAV (4) 5.9 ± 1.0 Jaundice, abdominal pain, and vomiting 1791 (739–3830)
.122 EBV (3) 9.7 ± 4.7 Jaundice and abdominal pain 159 (126–196)
CMV (7) 7.0 ± 6.9 Jaundice, fever, vomiting, and diarrhea 75 (70–260)
∗Kruskal-Wallistest for overall diﬀerence among the three groups.
Table 2: Spontaneous seroconversion (appearance HBeAb & loss of HbeAg) rate in children with Hepatitis B.
Spontaneous seroconversion Patients N (%, 95% CI) Age at seroconversion: years ± SD Time to seroconvert: years ± SD
At ﬁrst visit 10 (29.4%, 15–47%) 9.9 ±4.5N / A
At followup 12 (35.3%, 20–54%) 9.9 ±3.15 ±3.5
Total seroconversion 22 (64.9%, 46–80%) 9.9 ± 3.7N / A
No seroconversion 12 (35.3%, 20–4%) N/A N/A
glutamyl transpeptidase, bilirubin (conjugated and total),
and albumin. Coagulation status was assessed by prothrom-
bin time, partial thromboplastin time, and international
normalized ratio. Viral serology included hepatitis B surface
antigen(HbsAg),HepatitisBe Antigen(HbeAg),HepatitisB
surface antibody (HbsAb), Hepatitis B e antibody (HbeAb),
HepatitisA,HepatitisCserology, EBV,and CMV. HepatitisB
seroconversion was deﬁned as the appearance of HBeAb and
loss of HBeAg.
Allstatisticalanalyseswere conductedusing SAS9.1(SAS
Institute Inc., Cary, NC, USA). Normally distributed contin-
uous variables were summarized using mean and standard
deviations. Nonnormally distributed continuous variables
were summarized using median and interquartile range.
Categorical variables were summarized using frequency and
percentage. The percentages of seroconversion in the HBV
group were calculated along with an exact 95% conﬁdence
interval. The Kruskal-Wallis test was used in the overall
comparison of ALT level among the three acute hepatitis
groups due to the small number of patients and large
diﬀerences in the variance of ALT among groups.
3.Results
Atotalof261chartswere reviewed;however,only64patients
had conﬁrmed etiology. One patient was diagnosed with
herpes simplex virus hepatitis and was not included in the
analysis. There were 34 (53%) children with hepatitis B virus
(HBV), 16 (25%) with hepatitis C virus (HCV), 4 (6.3%)
with hepatitis A virus (HAV), 7 (11%) with CMV, and 3
(4.7%) with EBV. Demographics and clinical presentation
of patients with acute hepatitis (HAV, EBV, and CMV) are
reported in Table 1. Children with acute viral hepatitis had a
benign course; no child had fulminant hepatitis or required
liver transplantation. Serology for hepatitis E was not done.
Children with chronic hepatitis were symptom-free and
were screened after positive family history. Mean age of
children with HBV was 6.4 ± 4.6y e a r s .E t h n i cb a c k g r o u n d
included Black 11 (32.4%), Caucasian 6 (17.7%), South
East Asian 6 (17.7%), Arab 5 (14.7%), Chinese 3 (8.8%),
West Asian 2 (5.9%), and Korean 1 (2.9%). Children with
an HBV infection had mild elevation of liver function tests
with a median AST of 62IU/mL (interquartile range: 37–
113IU/mL) and a median ALT of 66IU/mL (interquartile
range: 32–105IU/mL). Nearly one third of patients (29%,
95% CI: 15–47%) with chronic HBV infection had sponta-
neous seroconversion at the ﬁrst clinic visit; mean age was
9.9 ± 4.5 years. Another 35% (95% CI: 20–54%) of children
seroconverted spontaneously at a mean followup of 5.0±3.5
years (mean age 9.9 ± 3.1 years). Seroconversion rates are
reported in Table 2. One patient with HBV was treated with
subcutaneous interferon α−2b at 3 years of age for 24 weeks
without success. This child spontaneously seroconverted at 7
years of age.
Children with HCV had a mean age of 8.4 ± 4.1y e a r s .
Ethnic backgrounds included Caucasian 9 (56.2%), Chinese
6(37.5%),andSoutheastAsian1(6.3%).Nopatientreceived
antiviral therapyagainst HCV.Elevationofliverenzymeswas
mild with a median AST of 58IU/mL (interquartile range:
36–80IU/mL) and a median ALT of 42IU/mL (interquartile
range: 33–65IU/mL).
4.Discussion
The number of children diagnosed with viral hepatitis with
a conﬁrmed etiology was low in our study. One possibility
is that a speciﬁc serology was not done and children were
discharged with a diagnosis of viral hepatitis of unknown
etiology. From those who had conﬁrmed viral etiology, we
found that only a quarter presented with acute hepatitis
r e l a t e dt oH A V ,E B V ,a n dC M V ,a n dm o s to ft h e mp r e s e n t e d
with jaundice and abdominal pain. It was found that the
elevation of liver enzymes in children with HAV was by
far the highest among the three acute hepatitis groups.
The CMV group had the lowest elevation of liver enzymes
although the overall test did not reach statistical signiﬁcance,
likely due to the small sample size.
The clinical course for children with acute hepatitis was
benign, and very few patients needed hospital admission.
There were no cases with acute liver failure or need for
liver transplantation. Contrary to our ﬁndings, Ciocca et al.
[7] reported a high incidence of acute liver failure due toISRN Pediatrics 3
HAV in an Argentinean population; this could be explained
by disease prevalence and geographical distribution. With
the advent of HAV vaccination, mild to fatal cases can be
prevented since HAV vaccine has proved eﬃcacious. For
instance the incidence of HAV has signiﬁcantly decreased in
the United States after implementing vaccination campaigns
[8]. In Canada, vaccination against HAV is currently recom-
mended to high-risk patients or people traveling to endemic
areas, autochthones cases are scarce as the incidence of HVA
is very low.
On the other hand, infection with EBV can be associated
with abnormal liver function tests in up to 80–90% of
cases and is often underdiagnosed [9]. It is well known
that EBV can also cause lymphoproliferative disorders par-
ticularly in children with underlying diseases or postorgan
transplantation [10]. It is likely that the number of children
with EBV-related hepatitis was underestimated in our study.
One can speculate that serology was probably not done.
Fortunately, the clinical course of EBV-related hepatitis in
immunocompetent patients is benign, and normalization of
liver function tests occurs with time.
Similarly, CMV is also a well-recognized cause of hep-
atitis, particularly in immunocompromised children (i.e.,
neonates and postorgan transplant) [11]. Seven children
had CMV-related hepatitis in our review; all of them were
immunocompetent and did not require antiviral therapy. In
contrast, Tezer et al. [12] reported the use of ganciclovir for
CMV hepatitis in immunocompetent children with excellent
response, speciﬁcally for those showing progression of the
disease. The use of antiviral therapy is not widely recom-
mended and is limited for immunocompromised patients.
Children with chronic viral hepatitis generally have a dif-
ferent course of disease. The majority are symptom-free, and
most of them had vertically transmitted infection [13]. The
incidence of HBV infection in childhood is not well known
and varies geographically. HBV spontaneous seroconversion
in our patient population occurred in approximately 65% of
children by age 9.9 years. Similar to our ﬁndings, Bortolotti
et al. [14] reported spontaneous seroconversion in 70% of
their children with chronic hepatitis B. The mechanisms
for seroconversion are not well known; however, it has
been proposed that age at the time of HBV infection,
HBV genotype, and host immune system plays a role in
this process [15]. Although all patients with HBV infection
may present long-term complications such as cirrhosis and
hepatocellular carcinoma, those who seroconvert have much
lower risk of developingthese conditions[16, 17].Preventive
measures such as implementing universal immunization
have signiﬁcantly reduced the incidence of HBV in diﬀerent
countries [18, 19], and Canada has not been the exception.
N o t a b l y ,t h e r ew e r em o r ec h i l d r e nw i t hc h r o n i cH B V
than HAV, both potentially preventable conditions with the
use of vaccination; this could be explained by the high
immigration rate from high HBV prevalent countries and
the chronicity it represents as opposed to the acute clinical
presentation on children with HAV infection. Approved
therapies in the United States for HBV include standard
interferon-alpha, lamivudine, and most recently adefovir in
adolescents [20]. Success rates vary depending on diﬀerent
factors including viral load and therapeutic agent; however,
the overall success rate ranges from 30% to 40%.
All children with HCV had vertical transmission and
were asymptomatic. Elevation of liver enzymes was mild,
and no child received antiviral therapy. Mild transaminitis
in childhood HCV was reported by Guido et al. [21]w h e r e
the degree of elevation of liver enzymes strongly correlated
to grading of focal necrosis in liver biopsies. Treatment with
ribavirin and pegylated interferon-alpha is recommended in
some particular cases [22].
In summary, viral hepatitis is frequently seen in our
clinical practice; however, most children with a discharge
diagnosis of viral hepatitis have no conﬁrmed etiology.
Children with acute or chronic viral hepatitis had a benign
course and had no long-term complications or need for liver
transplantation.
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